Depatuxizumab mafodotin

Depatuxizumab mafodotin
Monoclonal antibody
Type	Whole antibody
Source	Chimeric/humanized hybrid (mouse/human)
Target	EGFR
Clinical data
Other names	ABT-414
ATC code	none;
Identifiers
CAS Number	1585973-65-4;
ChemSpider	none;
UNII	F3R7A4P04N;
KEGG	D11019;
Chemical and physical data
Formula	C6624H10228N1728O2052S42
Molar mass	148251.25 g·mol−1

Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.^[1]^[2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.^[3]^[4]

This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.^[5]

In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.^[6] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.^[7] Phase I results were presented at ASCO in 2016.^[7]

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
^ "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org. 14 October 2016.
^ Nagayama A, Ellisen LW, Chabner B, Bardia A (December 2017). "Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments". Targeted Oncology. 12 (6): 719–739. doi:10.1007/s11523-017-0535-0. PMID 29116596. S2CID 1012740.
^ "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com. Retrieved 20 May 2019.
^ "Depatuxizumab mafodotin". en.pharmacodia.com.
^ ^a ^b "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Depatuxizumab_mafodotin
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.

[2] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).

[3] "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org. 14 October 2016.

[pmid29116596-4] Nagayama A, Ellisen LW, Chabner B, Bardia A (December 2017). "Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments". Targeted Oncology. 12 (6): 719–739. doi:10.1007/s11523-017-0535-0. PMID 29116596. S2CID 1012740.

[5] "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com. Retrieved 20 May 2019.

[6] "Depatuxizumab mafodotin". en.pharmacodia.com.

[springer.com-7] "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com.

[1]

[2]

[3]

[4]

[5]

[6]

[7]